Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD

Fineline Cube Jul 7, 2026
Company Deals

BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology

Fineline Cube Jul 7, 2026
Company Deals

Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal

Fineline Cube Jul 7, 2026
Company Deals

Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation

Fineline Cube Jul 7, 2026
Company Deals

Astex Pharmaceuticals, Genentech Forge $515M Breast Cancer Small Molecule Drug Collaboration

Fineline Cube Jul 7, 2026
Policy / Regulatory

Guangdong Launches “Spring Rain Action” to Accelerate Medical Device Innovation Transformation with 900+ Clinical Achievements Target

Fineline Cube Jul 7, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Fineline Cube Jul 6, 2026
Company Deals

Sino Biopharmaceutical’s F-star Therapeutics Inks Third Licensing Deal with Takeda for Immunotherapies

Fineline Cube Jul 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star...

Company Drug

3SBio Inc. Receives NMPA Approval for Nalfurafine Tablets to Treat Hemodialysis-Related Pruritus

Fineline Cube Jul 6, 2023

China-based 3SBio Inc. (HKG: 1530) has announced receiving marketing approval from the National Medical Products...

Company Deals

Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements

Fineline Cube Jul 6, 2023

China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Esflurbiprofen Patch Clinical Study

Fineline Cube Jul 6, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development

Fineline Cube Jul 6, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with...

Company Deals

Nanjing Kati Medical and Leman Biotech Partner to Advance Immune Metabolism Reprogramming in CAR-T Therapy

Fineline Cube Jul 6, 2023

Nanjing Kati Medical Technology Co., Ltd, a China-based company, has entered into a partnership with...

Company Deals

Brii Biosciences Expands Collaboration with VBI Vaccines on Hepatitis B Virus Therapies

Fineline Cube Jul 6, 2023

China-based Brii Biosciences Ltd (HKG: 2137) has announced an expanded license agreement with US firm...

Policy / Regulatory

NMPA Launches “Drug Standard Management Measures” to Enhance Drug Quality and Safety

Fineline Cube Jul 6, 2023

The National Medical Products Administration (NMPA) has released the “Drug Standard Management Measures,” a set...

Company Policy / Regulatory

China’s MofCOM Hosts Symposium with Multinational Corporations, Promises Development Opportunities

Fineline Cube Jul 6, 2023

This week, China’s Ministry of Commerce (MofCOM) convened a symposium attended by representatives from a...

Company Legal / IP

Genprex Inc. Receives Chinese Patent Protection for Reqorsa Immunogene Therapy

Fineline Cube Jul 6, 2023

Texas-based gene therapy company Genprex Inc., (NASDAQ: GNPX), has reported receiving a patent protection award...

Company

Moderna Inc. Plans USD 1 Billion Investment in Shanghai for mRNA Vaccine Production

Fineline Cube Jul 6, 2023

US-based mRNA specialist Moderna Inc. (NASDAQ: MRNA) has revealed further details of its entry into...

Company Drug

CSPC Pharmaceutical Group Receives Marketing Approval for Desvenlafaxine in China

Fineline Cube Jul 6, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving marketing approval in China for...

Company Drug

AbbVie’s Rinvoq Receives NMPA Approval for Moderate to Severe Crohn’s Disease Treatment

Fineline Cube Jul 6, 2023

US pharmaceutical firm AbbVie (NYSE: ABBV) has announced receiving market approval from the National Medical...

Company Drug

Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment

Fineline Cube Jul 5, 2023

Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...

Policy / Regulatory

CDE Releases 72nd Batch of Generic Reference Preparations with New Specifications

Fineline Cube Jul 5, 2023

The Center for Drug Evaluation (CDE) has released the 72nd batch of chemical generic reference...

Company Drug

Huadong Medicine’s Liraglutide Biosimilar Gains NMPA Approval for Weight Loss Indication

Fineline Cube Jul 5, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received additional indication...

Company Drug

Abbisko Therapeutics’ EGFR Inhibitor ABSK112 Clears FDA for Global Phase I NSCLC Study

Fineline Cube Jul 5, 2023

Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...

Company Drug

Jacobio Pharma’s KRAS Inhibitor Glecirasib Advances to Pivotal Pancreatic Cancer Trial

Fineline Cube Jul 5, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that it has received the green light from...

Company Drug

InnoCare Pharma Initiates Clinical Trial for TYK2 Inhibitor ICP-488 in Psoriasis Patients

Fineline Cube Jul 5, 2023

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced a significant milestone in the clinical...

Company Medical Device

ZAP-X Gyroscopic Radiosurgery Platform Receives NMPA Approval for Brain Tumor Treatment

Fineline Cube Jul 5, 2023

US-based Zap Surgical Systems Inc. has announced that it has received market approval in China...

Posts pagination

1 … 531 532 533 … 691

Recent updates

  • cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD
  • BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology
  • Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal
  • Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation
  • Guangdong Launches “Spring Rain Action” to Accelerate Medical Device Innovation Transformation with 900+ Clinical Achievements Target
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD

Company Deals

BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology

Company Deals

Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal

Company Deals

Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.